178 related articles for article (PubMed ID: 37923056)
81. Optimizing regional chemotherapy for epithelial ovarian cancer.
Sugarbaker PH
J Obstet Gynaecol Res; 2022 Jun; 48(6):1306-1317. PubMed ID: 35343033
[TBL] [Abstract][Full Text] [Related]
82. Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease.
Monk BJ; Pujade-Lauraine E; Burger RA
Ann Oncol; 2013 Dec; 24 Suppl 10():x53-x58. PubMed ID: 24265406
[TBL] [Abstract][Full Text] [Related]
83. Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients: results of an individual participant data meta-analysis in 1213.
Woopen H; Richter R; Chekerov R; Inci G; Alavi S; Grabowski JP; Sehouli J
Support Care Cancer; 2020 Jan; 28(1):73-78. PubMed ID: 30980260
[TBL] [Abstract][Full Text] [Related]
84. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.
Haunschild CE; Tewari KS
Future Oncol; 2020 Mar; 16(7):225-246. PubMed ID: 31746224
[TBL] [Abstract][Full Text] [Related]
85. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
86. Research progress in the treatment of partial platinum-sensitive recurrent ovarian cancer.
Zhu M; Wang J; Wuna Y; Wang Y; Li H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Jun; 46(6):644-652. PubMed ID: 34275934
[TBL] [Abstract][Full Text] [Related]
87. Metronomic chemotherapy and immunotherapy in cancer treatment.
Chen YL; Chang MC; Cheng WF
Cancer Lett; 2017 Aug; 400():282-292. PubMed ID: 28189534
[TBL] [Abstract][Full Text] [Related]
88. Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Epithelial Ovarian Cancer: A Debated Issue for Gynecologic Oncologists.
Gadducci A; Cosio S; Lippolis PV
Anticancer Res; 2022 Oct; 42(10):4659-4665. PubMed ID: 36191972
[TBL] [Abstract][Full Text] [Related]
89. An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
Gore M; Hackshaw A; Brady WE; Penson RT; Zaino R; McCluggage WG; Ganesan R; Wilkinson N; Perren T; Montes A; Summers J; Lord R; Dark G; Rustin G; Mackean M; Reed N; Kehoe S; Frumovitz M; Christensen H; Feeney A; Ledermann J; Gershenson DM
Gynecol Oncol; 2019 Jun; 153(3):541-548. PubMed ID: 31005287
[TBL] [Abstract][Full Text] [Related]
90. Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer.
Gille J; Spieth K; Kaufmann R
J Dtsch Dermatol Ges; 2005 Jan; 3(1):26-32. PubMed ID: 16353746
[TBL] [Abstract][Full Text] [Related]
91. Metronomic therapy for gynecologic cancers.
Su WH; Ho TY; Li YT; Lu CH; Lee WL; Wang PH
Taiwan J Obstet Gynecol; 2012 Jun; 51(2):167-78. PubMed ID: 22795090
[TBL] [Abstract][Full Text] [Related]
92. State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer.
Singh N; Badrun D; Ghatage P
Expert Opin Pharmacother; 2020 Sep; 21(13):1579-1590. PubMed ID: 32552175
[TBL] [Abstract][Full Text] [Related]
93. Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial.
Patil V; Noronha V; Dhumal SB; Joshi A; Menon N; Bhattacharjee A; Kulkarni S; Ankathi SK; Mahajan A; Sable N; Nawale K; Bhelekar A; Mukadam S; Chandrasekharan A; Das S; Vallathol D; D'Souza H; Kumar A; Agrawal A; Khaddar S; Rathnasamy N; Shenoy R; Kashyap L; Rai RK; Abraham G; Saha S; Majumdar S; Karuvandan N; Simha V; Babu V; Elamarthi P; Rajpurohit A; Kumar KAP; Srikanth A; Ravind R; Banavali S; Prabhash K
Lancet Glob Health; 2020 Sep; 8(9):e1213-e1222. PubMed ID: 32827483
[TBL] [Abstract][Full Text] [Related]
94. Epithelial Ovarian Cancer and Cancer Stem Cells.
Soliman AA; Elzarkaa AA; Malik E
Adv Exp Med Biol; 2021; 1330():21-32. PubMed ID: 34339028
[TBL] [Abstract][Full Text] [Related]
95. Targeted drug conjugate systems for ovarian cancer chemotherapy.
Ogundipe OD; Olajubutu O; Adesina SK
Biomed Pharmacother; 2023 Sep; 165():115151. PubMed ID: 37473683
[TBL] [Abstract][Full Text] [Related]
96. Challenges for chemotherapy in ovarian cancer.
Ozols RF
Ann Oncol; 2006 May; 17 Suppl 5():v181-7. PubMed ID: 16807453
[TBL] [Abstract][Full Text] [Related]
97. Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer.
Wood GE; Ledermann JA
Best Pract Res Clin Obstet Gynaecol; 2022 Jan; 78():64-73. PubMed ID: 34607745
[TBL] [Abstract][Full Text] [Related]
98. Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
Wolford JE; Bai J; Moore KN; Kristeleit R; Monk BJ; Tewari KS
Gynecol Oncol; 2020 May; 157(2):500-507. PubMed ID: 32173049
[TBL] [Abstract][Full Text] [Related]
99. Targeted therapies for treatment of recurrent ovarian cancer.
Grisham RN; Hyman DM; Iyer G
Clin Adv Hematol Oncol; 2014 Mar; 12(3):158-62. PubMed ID: 24927263
[TBL] [Abstract][Full Text] [Related]
100. Immunotherapy May Improve Tumor Sensitivity to Palliative Chemotherapy in Platinum Resistant Ovarian Cancer.
Kinney RE; Nair S; Kim CH; Thomas MB; DelaTorre M
Oncologist; 2023 Jun; 28(6):e478-e486. PubMed ID: 37027520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
